Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

TB and M/XDR-TB infection control in European TB reference centres: the Achilles’ heel?

G. Sotgiu, L. D’Ambrosio, R. Centis, G. Bothamley, D.M. Cirillo, S. De Lorenzo, G. Guenther, K. Kliiman, R. Muetterlein, V. Spinu, M. Villar, J.P. Zellweger, A. Sandgren, E. Huitric, C. Lange, D. Manissero, G.B. Migliori
European Respiratory Journal 2011 38: 1221-1223; DOI: 10.1183/09031936.00029311
G. Sotgiu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. D’Ambrosio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Centis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Bothamley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D.M. Cirillo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. De Lorenzo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Guenther
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Kliiman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Muetterlein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V. Spinu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Villar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.P. Zellweger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Sandgren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Huitric
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Lange
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Manissero
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G.B. Migliori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: giovannibattista.migliori@fsm.it
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editors:

The emergence of multidrug-resistant (MDR) tuberculosis (TB), defined as in vitro resistance to isoniazid and rifampicin, and extensively drug-resistant (XDR)-TB, defined as in vitro drug resistance to isoniazid and rifampicin plus any fluoroquinolone and at least one of the injectable drugs (amikacin, capreomycin or kanamycin), represents a major threat to TB control at the global level [1–5]. XDR-TB is a manmade product, resulting, in essence, from clinical mismanagement of newly diagnosed susceptible and resistant TB cases [2–5]. Moreover, existing MDR/XDR-TB cases must be promptly detected and treated, and the transmission from infectious source cases has to be prevented, particularly in nosocomial settings [2–6].

The World Health Organization (WHO), in its Stop TB Strategy [7] and its recent Policy on Infection Control [8], clearly underlines the importance of implementing effective measures of infection control in clinical facilities managing TB and MDR-TB patients. At present, no international study is available to investigate how infection control measures are implemented in healthcare facilities managing TB patients.

The aim of the present study was to document how infection control measures are implemented in selected settings in the European Union, focusing on national MDR/XDR-TB reference centres.

A standardised and comprehensive survey tool was developed, as discussed previously [9, 10]. In summary, the tool consisted of items covering the key areas that a panel of experts considered adequate to evaluate TB infection control in the selected countries. A Delphi process was used to identify the key elements belonging to infection control, and to assign priorities to the questions proposed and define a weighted score to the answers obtained. The items relate to individual patients (risk factors for MDR-TB) and institutional factors (table 1).

View this table:
  • View inline
  • View popup
Table 1– Infection control implementation in tuberculosis (TB) reference centres of five European countries, 2009–2010

The final version of the tool was composed of three parts and one annex: part 1 summarised the features of the setting surveyed (62 items); part 2 collected information on individual clinical records surveyed (one line per clinical case; 141 items); and part 3 allowed comparison of the key case management decisions taken on each individual case against internationally agreed standards (25 scored questions). The international reference standards used to define the highest-standard practice for comparison were derived from the WHO Policy on Infection Control [8] and the International Standards for Tuberculosis Care document [11].

The tool was applied to each individual original patient record examined, and adherence/nonadherence entered on the electronic data collection sheet and, finally, a score. The survey teams, including clinical and public health experts, were trained to use the tool, define adherence/nonadherence to standards and assign the score.

The original records of 40 TB/MDR-TB cases were assessed at each study site, including 30 MDR-TB and 10 other than MDR-TB cases (i.e. the strain being susceptible, monoresistant or polyresistant), between November 2009 and March 2010. The clinical files of the cases to survey were selected by the study site counterparts before the visit, following a time criterion (cases treated since January 1, 2005) for a simple random sampling.

The TB reference institutions, identified in collaboration with national health authorities (ministries of health), were identified in five countries illustrative of the different TB epidemiology patterns in Europe (table 1). As per ECDC policy, the selected countries cannot be disclosed.

Categorical variables were compared by Chi-squared or Fisher’s exact tests where appropriate. A p-value of ≤0.05 was deemed statistically significant. Data were analysed using Stata 11.0 (StataCorp, College Station, TX, USA).

The main findings are described in table 1. 40 medical records were assessed per country.

Individual risk factors were generally well documented: investigation of previous TB diagnosis was performed in 186 (93%) out of 200 TB cases admitted to the reference centres, although only 160 (80%) out of 200 of their contacts were investigated, which is potentially relevant from a public health perspective.

Although healthcare workers were sufficiently protected in the majority of cases (199 (99.5%) out of 200 cases) and respirators were always available (200 (100%) out of 200 cases), 40 (20%) out of 200 cases were not educated on cough etiquette and other important infection control issues.

No negative-pressure room (including a ventilation system designed so that air flows from the corridors, or any adjacent area, into the negative-pressure room, ensuring that contaminated air cannot escape from the negative-pressure room to other parts of the facility) was identified in four out of five surveyed centres.

Furthermore, specialised training in infection control and healthcare epidemiology was not offered to the individuals employed in the centres surveyed by professional organisations or scientific societies, and respirator fitting was never tested. No specific programme for the implementation of good infection control practice was in place. A surveillance system for monitoring mycobacterial drug resistance covered all cases, although an infection control committee was in place at the time of admission for 160 (80%) out of 200 cases.

The reference centre located in the group 5 country exemplified the main shortcomings: the proportions scored on investigation of previous TB diagnosis, contact investigation, infection control committee, cough etiquette and staff training were significantly lower (p<0.05) than those in the other countries. Environmental measures (i.e. methods used to decrease the quantity of droplet nuclei and to control their direction in the air) were inadequate in group 2 and 5 countries (p<0.001).

The main area of concern was the lack of a comprehensive infection control strategy or plan in all the centres surveyed, reflecting a lack of central-level planning [9]. Administrative measures (infection control committees) were not systematically in place. A plan is a key instrument to activating and empowering the necessary committees, and ensuring that the key infection control activities are implemented and evaluated. The pitfalls identified in the areas of training and health education would benefit from the implementation of infection control plans at the facility level. The lack of planning at the facility level reflects a lack of planning at the central level on this given issue.

In terms of personal protection, although respirators were in place and used by staff, and surgical masks by patients, respirator fit was not tested in any of the centres. It is known that a proportion of staff do not pass respirator fit testing, due to inadequate positioning of the respirator [12]. A respirator placed wrongly on the mouth and nose offers a false sense of security, and a lack of real protection from Mycobacterium tuberculosis infection cannot be excluded [9, 12].

The lack of negative-pressure ventilation in all but one of the centres surveyed deserves a special discussion. Sufficient respiratory isolation rooms for all new patients admitted (at least until the exact resistance pattern is identified and/or the patient is rendered noninfectious) and adequate isolation procedures need to be available in centres diagnosing and treating TB. Although a lack of negative-pressure ventilation rooms, even for MDR-TB cases, has been identified, no evidence was found that this caused secondary cases among healthcare staff (e.g. a single TB case was identified in one country over a 10-yr period as a result of this survey). A critical review of the available evidence and clear recommendations on this procedure seem to be justified.

According to the results of this survey, administrative and personal protection measures (e.g. masks for patients or respirators for healthcare staff) should be scaled up, as they are relevant in preventing secondary TB cases among staff. Furthermore, adequate health education practices for patients (e.g. cough etiquette) coupled with regular training of staff are necessary to ensure good infection control results.

The results of our study clearly demonstrate that even in European MDR/XDR-TB reference centres, infection control measures do not fully comply with international recommendations and margins exist for prompt public health action aiming at minimising TB transmission in nosocomial settings.

Footnotes

  • Support Statement

    The research leading to this publication has been performed under the European Centre for Disease Prevention and Control (ECDC) service contract 1757 adjudicated to TBNET following open tender competition.

  • Statement of Interest

    None declared.

  • ©ERS 2011

REFERENCES

  1. ↵
    World Health Organization. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB). 2010 Global Report on Surveillance and Response. WHO/HTM/TB/2010.3. Geneva, World Health Organization, 2010.
  2. ↵
    1. Sotgiu G,
    2. Ferrara G,
    3. Matteelli A,
    4. et al
    . Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871–881.
    OpenUrlAbstract/FREE Full Text
    1. Migliori GB,
    2. Loddenkemper R,
    3. Blasi F,
    4. et al
    . 125 years after Robert Koch’s discovery of the tubercle bacillus – the new XDR-TB threat. Is “science” enough to tackle the epidemic?. Eur Respir J 2007; 29: 423–427.
    OpenUrlFREE Full Text
    1. Migliori GB,
    2. Besozzi G,
    3. Girardi E,
    4. et al
    . Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623–626.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Migliori GB,
    2. Ortmann J,
    3. Girardi E,
    4. et al
    . Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis 2007; 13: 780–782.
    OpenUrlPubMedWeb of Science
  4. ↵
    World Health Organization. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006; 81: 430–432.
    OpenUrlPubMed
  5. ↵
    1. Raviglione MC,
    2. Uplekar MW
    . WHO’s new Stop TB Strategy. Lancet 2006; 367: 952–955.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    World Health Organization. WHO Policy on Infection Control in Health-Care Facilities, Congregate Settings and Households. WHO/HTM/TB/2009.419. Geneva, World Health Organization, 2009.
  7. ↵
    1. Sotgiu G,
    2. Centis R,
    3. D’Ambrosio L,
    4. et al
    . Development of a standardised tool to survey MDR-/XDR-TB case management in Europe. Eur Respir J 2010; 36: 208–211.
    OpenUrlFREE Full Text
  8. ↵
    1. Miravitlles M,
    2. Ferrara G,
    3. Lange C,
    4. et al
    . TB or not TB: update from the ERS Respiratory Infection Assembly 10. Eur Respir J 2010; 36: 665–670.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC), 2nd Edn. The Hague, Tuberculosis Coalition for Technical Assistance, 2009.
  10. ↵
    1. Nardell E,
    2. Dharmadhikari A
    . Turning off the spigot: reducing drug-resistant tuberculosis transmission in resource-limited settings. Int J Tuberc Lung Dis 2010; 14: 1233–1243.
    OpenUrlPubMed
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 38 Issue 5 Table of Contents
European Respiratory Journal: 38 (5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
TB and M/XDR-TB infection control in European TB reference centres: the Achilles’ heel?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
TB and M/XDR-TB infection control in European TB reference centres: the Achilles’ heel?
G. Sotgiu, L. D’Ambrosio, R. Centis, G. Bothamley, D.M. Cirillo, S. De Lorenzo, G. Guenther, K. Kliiman, R. Muetterlein, V. Spinu, M. Villar, J.P. Zellweger, A. Sandgren, E. Huitric, C. Lange, D. Manissero, G.B. Migliori
European Respiratory Journal Nov 2011, 38 (5) 1221-1223; DOI: 10.1183/09031936.00029311

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
TB and M/XDR-TB infection control in European TB reference centres: the Achilles’ heel?
G. Sotgiu, L. D’Ambrosio, R. Centis, G. Bothamley, D.M. Cirillo, S. De Lorenzo, G. Guenther, K. Kliiman, R. Muetterlein, V. Spinu, M. Villar, J.P. Zellweger, A. Sandgren, E. Huitric, C. Lange, D. Manissero, G.B. Migliori
European Respiratory Journal Nov 2011, 38 (5) 1221-1223; DOI: 10.1183/09031936.00029311
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • How can we achieve better prevention of TB among contacts?
  • Predictors of treatment outcome in MDR-TB in Portugal
  • Drug concentration in lung tissue in MDR-TB
Show more Letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society